Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Hldgs is well positioned for success in the biotherapeutics market as it continues to develop and advance its proprietary RaniPill technology. Regulatory risks may impact the timeline of clinical development, but with strong financials and promising early data from its Phase I clinical study for RT-114, the company is poised for potential future growth and partnerships. It will be important to monitor the release of Phase I data and any updates on potential Phase 2 trials for RT-114 in the coming months.

Bears say

Rani Therapeutics Hldgs is a clinical-stage biotherapeutics company that has shown promise with its RaniPill technology, which aims to replace painful injections with oral dosing. However, there is a significant risk of competition from other companies developing similar technologies and a high likelihood of differences in efficacy and safety data as the company's platform advances into multiple dose studies. Management turnover and the need for continued financing also add to the risks for this company. Considering these factors, we believe there is a negative outlook for Rani Therapeutics Hldgs' stock.

RANI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 3 analysts, RANI has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.